Fernández ÁJD

Language: Spanish
References: 9
Page: 420-422
PDF size: 41.07 Kb.

Text Extraction

No abstract.

REFERENCES

1. Surveillance epidemiology and end results. Fast Stats: an interactive tool for access to SEER cancer statistics, Surveillance Research Program. National Cancer Institute. 2016. Citado: abril 27, 2016. Disponible en: http://seer.cancer.gov/faststats.

2. Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011; 118(17):4519-29.

3. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27(17):2758-2765.

4. San Miguel JF. Introduction to a series of reviews on multiple myeloma. Blood. 2015; 125(20):3039-40.

5. Lonial S, Boise LH, Kaufman J. How I treat high-risk myeloma. Blood. 2015; 126(13):1536-43.

6. Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplantation. 2016; 51:492-500.

7. Sriskandarajah P, Davies FE. Multiple myeloma: optimal management and long-term disease control. Blood and Lymphatic Cancer: Targets and Therapy. 2014:121-34.

8. Fernández Aguila JD, García Blay A, Corona Martínez LA, Cabrera Zamora MM, Prieto Jiménez L, Guerra Alfonso T. Supervivencia a los 3 años de pacientes con mieloma múltiple. Medisur. 2006; 4(3):8-13.

9. Ramón Rodríguez LG, Rivera-Keeling C, Arencibia-Núñez A, Avila-Cabrera OM, Izquierdo-Cano L, Espinosa-Estrada E, et al . Caracterización clínica y de laboratorio del mieloma múltiple en el Instituto de Hematología e Inmunología. Rev Cubana Hematol Inmunol Hemoter. 2013 Dic; 29(4):382-97.